Drug Profile
Rintodestrant - G1 Therapeutics
Alternative Names: G1T-48Latest Information Update: 19 Apr 2023
Price :
$50
*
At a glance
- Originator University of Illinois
- Developer G1 Therapeutics
- Class 2 ring heterocyclic compounds; Antineoplastics; Benzene derivatives; Carboxylic acids; Ethers; Fluorobenzenes; Small molecules; Thiophenes
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Breast cancer; HER2 negative breast cancer
Most Recent Events
- 19 Apr 2023 Discontinued - Phase-I/II for HER2-negative-breast-cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Belgium (PO)
- 19 Apr 2023 Discontinued - Phase-I/II for HER2-negative-breast-cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Bulgaria (PO)
- 19 Apr 2023 Discontinued - Phase-I/II for HER2-negative-breast-cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Georgia (PO)